| EC | endometrial cancer |
| EMT | epithelial—mesenchymal transition |
| TCGA | The Cancer Genome Atlas |
| GEO | Gene Expression Omnibus |
| EPHB2 | EPH receptor B2 |
| TUFT1 | tuftelin 1 |
| CDKN2A | cyclin-dependent kinase inhibitor 2A |
| ONECUT2 | one cut homeobox 2 |
| RBP2 | retinol-binding protein 2 |
| KLF8 | Kruppel-like factor 8 |
| E2F1 | E2F transcription factor 1 |
| SIX1 | SIX homeobox 1 |
| ERBB2 | Erb-b2 receptor tyrosine kinase 2 |
| RS | risk score |
| ESTIMATE | estimation of stromal and immune cells in malignant tumor tissues using expression data |
| ICB | immune checkpoint blockade |
| TIDE | tumor immune dysfunction and exclusion |
| GDSC | Genomics of Drug Sensitivity in Cancer |
| ERGs | EMT-related genes |
| UCEC | uterine corpus endometrial carcinoma |
| ROC | receiver-operating characteristic |
| TME | tumor microenvironment |
| LASSO | least absolute shrinkage and selection operator |
| IC50 | the half-maximal inhibitory concentration |
| FDR | false discovery rate |
| MMRd | mismatch repair-deficient |
| CTLA-4 | cytotoxic T-lymphocyte antigen 4 |
| PD-L1 | programmed cell death-ligand 1 |
| FIGO | The International Federation of Gynecology and Obstetrics |
| AUC | area under the curve |
| OS | overall survival |
| DFS | disease-free survival |